Japanese drug major Eisai (TYO: 4523) and Shinshu University venture company Anaeropharma Science last week concluded an option agreement for APS001, a novel anticancer agent currently under development at Anaeropharma that utilizes characteristic features of Bifidobacterium longum, as well as an accord on the discovery of novel anticancer agents that utilize Bifidobacterium as a drug delivery system.
The two contracts cover the development of drugs that utilize obligate anaerobes and non-pathogenic bacteria, traits which are characteristic of Bifidobacterium, a human intestinal tract bacterium. Financial terms of the deals were not disclosed.
Under the terms of the first deal, Eisai acquires the right of first review regarding the results of the Phase I clinical trials for APS001, which are scheduled to be conducted in the USA by Anaeropharma, and the right of first refusal on the licensing of the compound under development. Eisai will compensate Anaeropharma these two priority rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze